{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:39:53Z","timestamp":1784990393663,"version":"3.55.0"},"reference-count":31,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b17-00499","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T22:12:05Z","timestamp":1509487925000},"page":"1948-1955","source":"Crossref","is-referenced-by-count":17,"title":["Alterations in Cisplatin Pharmacokinetics and Its Acute\/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats"],"prefix":"10.1248","volume":"40","author":[{"given":"Akira","family":"Okada","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Hamori","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Faculty of Pharmaceutical Science, Doshisha Women\u2019s College of Liberal Arts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Faculty of Pharmaceutical Science, Doshisha Women\u2019s College of Liberal Arts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Faculty of Pharmaceutical Science, Doshisha Women\u2019s College of Liberal Arts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Sugioka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Faig J, Haughton M, Taylor RC, D\u2019Agostino RB Jr, Whelen MJ, Porosnicu Rodriguez KA, Bonomi M, Murea M, Porosnicu M. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. <i>Am. J. Clin. Oncol.<\/i>, <b>2016<\/b>, 1 (2016)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>11<\/b>, 1173\u20131179 (2016).","DOI":"10.2215\/CJN.08070715"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Cole WC, Wolf W. Preparation and metabolism of a cisplatin\/serum protein complex. <i>Chem. Biol. Interact.<\/i>, <b>30<\/b>, 223\u2013235 (1980).","DOI":"10.1016\/0009-2797(80)90128-3"},{"key":"4","unstructured":"4) Hanada K, Ninomiya K, Ogata H. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin. <i>J. Pharm. Pharmacol.<\/i>, <b>52<\/b>, 1345\u20131353 (2000)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. <i>Clin. Pharmacol. Ther.<\/i>, <b>86<\/b>, 396\u2013402 (2009).","DOI":"10.1038\/clpt.2009.139"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. <i>Biochem. Pharmacol.<\/i>, <b>80<\/b>, 1762\u20131767 (2010).","DOI":"10.1016\/j.bcp.2010.08.019"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Arany I, Safirstein RL. Cisplatin nephrotoxicity. <i>Semin. Nephrol.<\/i>, <b>23<\/b>, 460\u2013464 (2003).","DOI":"10.1016\/S0270-9295(03)00089-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. <i>J. Pharmacol. Sci.<\/i>, <b>100<\/b>, 65\u201372 (2006).","DOI":"10.1254\/jphs.FP0050661"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ, Fayyazi A. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK\/ERK activation. <i>Br. J. Cancer<\/i>, <b>91<\/b>, 589\u2013598 (2004).","DOI":"10.1038\/sj.bjc.6601919"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>322<\/b>, 8\u201315 (2007).","DOI":"10.1124\/jpet.107.119792"},{"key":"11","unstructured":"11) Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. <i>Clin. Pharmacol. Ther.<\/i>, <b>94<\/b>, 585\u2013592 (2013)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kim HJ, Park DJ, Kim JH, Jeong EY, Jung MH, Kim TH, Yang JI, Lee GW, Chung HJ, Chang SH. Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation. <i>J. Pharmacol. Sci.<\/i>, <b>127<\/b>, 117\u2013126 (2015).","DOI":"10.1016\/j.jphs.2014.11.009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Miyaji T, Kato A, Yasuda H, Fujigaki Y, Hishida A. Role of the increase in p21 in cisplatin-induced acute renal failure in rats. <i>J. Am. Soc. Nephrol.<\/i>, <b>12<\/b>, 900\u2013908 (2001).","DOI":"10.1681\/ASN.V125900"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Mizushima Y, Nagahama H, Yokoyama A, Morikage T, Yano S. Studies on nephrotoxicity following a single and repeated administration of <i>cis<\/i>-diamminedichloroplatinum (CDDP) in rats. <i>Tohoku J. Exp. Med.<\/i>, <b>151<\/b>, 129\u2013135 (1987).","DOI":"10.1620\/tjem.151.129"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. <i>Asian Pac. J. Cancer Prev.<\/i>, <b>16<\/b>, 1117\u20131122 (2015).","DOI":"10.7314\/APJCP.2015.16.3.1117"},{"key":"16","unstructured":"16) Martinez G, Costantino G, Clementi A, Puglia M, Clementi S, Cantarella G, De Meo L, Matera M. Cisplatin-induced kidney injury in the rat: L-carnitine modulates the relationship between MMP-9 and TIMP-3. <i>Exp. Toxicol. Pathol.<\/i>, <b>61<\/b>, 183\u2013188 (2009)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Guinee DG Jr, van Zee B, Houghton DC. Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. <i>Cancer<\/i>, <b>71<\/b>, 4050\u20134054 (1993).","DOI":"10.1002\/1097-0142(19930615)71:12<4050::AID-CNCR2820711240>3.0.CO;2-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Minakata K, Nozawa H, Okamoto N, Suzuki O. Determination of platinum derived from cisplatin in human tissues using electrospray ionization mass spectrometry. <i>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.<\/i>, <b>832<\/b>, 286\u2013291 (2006).","DOI":"10.1016\/j.jchromb.2006.01.016"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Minakata K, Nozawa H, Suzuki M, Gonmori K, Yamagishi I, Watanabe K, Suzuki O. Trace analysis of platinum in blood and urine by ESI-MS-MS. <i>Forensic.<\/i> <i>Toxicol.<\/i>, <b>25<\/b>, 284\u2013287 (2007).","DOI":"10.1007\/s11419-007-0034-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. <i>Nephron Clin. Pract.<\/i>, <b>120<\/b>, c179\u2013c184 (2012).","DOI":"10.1159\/000339789"},{"key":"21","unstructured":"21) Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, Zeeuw DDE, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). <i>Kidney Int.<\/i>, <b>67<\/b>, 2089\u20132100 (2005)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yamate J, Sato K, Ide M, Nakanishi M, Kuwamura M, Sakuma S, Nakatsuji S. Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. <i>Vet. Pathol.<\/i>, <b>39<\/b>, 322\u2013333 (2002).","DOI":"10.1354\/vp.39-3-322"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Gonz\u00e1lez R, Romay C, Borrego A, Hern\u00e1ndez F, Merino N, Zamora Z, Rojas E. Lipid peroxides and antioxidant enzymes in cisplatin-induced chronic nephrotoxicity in rats. <i>Mediators Inflamm.<\/i>, <b>2005<\/b>, 139\u2013143 (2005).","DOI":"10.1155\/MI.2005.139"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Dodder NG, Tai SS, Sniegoski LT, Zhang NF, Welch MJ. Certification of creatinine in a human serum reference material by GC-MS and LC-MS. <i>Clin. Chem.<\/i>, <b>53<\/b>, 1694\u20131699 (2007).","DOI":"10.1373\/clinchem.2007.090027"},{"key":"25","unstructured":"25) Fukushima K, Okada A, Sasaki K, Kishimoto S, Fukushima S, Hamori M, Nishimura A, Shibata N, Shirai T, Terauchi R, Kubo T, Sugioka N. Population pharmacokinetic-toxicodynamic modeling and simulation of cisplatin-induced acute renal injury in rats: effect of dosing rate on nephrotoxicity. <i>J. Pharm. Sci.<\/i>, <b>105<\/b>, 324\u2013332 (2016)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nadasdy T, Laszik Z, Blick KE, Johnson LD, Silva FG. Proliferative activity of intrinsic cell populations in the normal human kidney. <i>J. Am. Soc. Nephrol.<\/i>, <b>4<\/b>, 2032\u20132039 (1994).","DOI":"10.1681\/ASN.V4122032"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Thomasova D, Anders HJ. Cell cycle control in the kidney. <i>Nephrol. Dial. Transplant.<\/i>, <b>30<\/b>, 1622\u20131630 (2015).","DOI":"10.1093\/ndt\/gfu395"},{"key":"28","unstructured":"28) Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, Boulikas T. Low renal toxicity of lipoplatin compared to cisplatin in animals. <i>Anticancer Res.<\/i>, <b>24<\/b>, 2193\u20132200 (2004)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Takahashi A, Kimura T, Takabatake Y, Namba T, Kaimori J, Kitamura H, Matsui I, Niimura F, Matsusaka T, Fujita N, Yoshimori T, Isaka Y, Rakugi H. Autophagy guards against cisplatin-induced acute kidney injury. <i>Am. J. Pathol.<\/i>, <b>180<\/b>, 517\u2013525 (2012).","DOI":"10.1016\/j.ajpath.2011.11.001"},{"key":"30","unstructured":"30) Hanada K, Suda M, Kanai N, Ogata H. Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives. <i>Pharm. Res.<\/i>, <b>27<\/b>, 1893\u20131899 (2010)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Uozumi J, Ueda T, Yasumasu T, Koikawa Y, Naito S, Kumazawa J, Kamura T, Nakano H, Sueishi K. Platinum accumulation in the kidney and changes in creatinine clearance following chemotherapy with cisplatin in humans. <i>Urol. Int.<\/i>, <b>51<\/b>, 57\u201361 (1993).","DOI":"10.1159\/000282514"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/11\/40_b17-00499\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:27:06Z","timestamp":1659745626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/11\/40_b17-00499\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00499","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}